Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MOGAT2 | Q3SYC2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MGAT2 | Q10469 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471107 | 1.00 | ESR1 (0.50) | ESR1ESR2PKMRAB9AMOGAT2 | |
| SCHEMBL25214054 | 1.00 | ESR1 (0.50) | ESR1ESR2PKMRAB9AMOGAT2 | |
| SCHEMBL30471056 | 0.93 | RAB9A (0.47) | ESR1ESR2PKMRAB9AMOGAT2 | |
| SCHEMBL25590981 | 0.93 | RAB9A (0.47) | ESR1ESR2PKMRAB9AMOGAT2 | |
| SCHEMBL30471123 | 0.91 | ESR1 (0.49) | ESR1ESR2PKMRAB9AGAA | |
| SCHEMBL25250672 | 0.91 | ESR1 (0.49) | ESR1ESR2PKMRAB9AGAA | |
| SCHEMBL25250671 | 0.91 | ESR1 (0.49) | ESR1ESR2PKMRAB9AGAA | |
| SCHEMBL30471234 | 0.88 | ESR1 (0.50) | ESR1ESR2PKMRAB9AMOGAT2 | |
| SCHEMBL25590650 | 0.88 | ESR1 (0.50) | ESR1ESR2PKMRAB9AMOGAT2 | |
| SCHEMBL25267628 | 0.88 | RAB9A (0.49) | RAB9AMOGAT2GAAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136552-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| WO-2023094828-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136552-A1 | ANTAGONISTS OF CAV 2.3 | CACNA1E, CACNA1A, CACNA1S | ESR1 4309/4885ESR2 2687/4885PKM 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.